Natural killer cell therapy before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding natural killer (NK) cell therapy to standard chemotherapy and a PD-1 inhibitor (a type of immunotherapy) before surgery can help shrink early-stage non-small cell lung cancer and improve outcomes. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have non-small cell lung cancer that is stage IB to IIIA and can be removed with surgery.
- You cannot have had any prior cancer treatment (like chemotherapy, radiation, or immunotherapy).
- Your tumor must not have certain gene changes (EGFR or ALK).
- You must be in good enough health to do light activities (performance status 0 or 1).
- You must have adequate organ function (bone marrow, liver, kidneys) and a life expectancy of more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
This trial tests combining natural killer (NK) cells with an immunotherapy drug as a maintenance treatment after standard chemotherapy for small cell lung cancer that has spread. The goal is to see if this combination can help keep the cancer from growing.
Hear when a new Resectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.